Radiation therapy of esophageal cancer.
Radiation therapy has been used extensively in the management of patients with cancer of the esophagus. It has demonstrated an ability to cure a small minority of patients. Cure is likely to be limited to patients who have lesions less than 5 cm in length and have minimal, if any, involvement of lymph nodes. Esophagectomy is likely to cure a similar, small percentage of patients with the same presentation of minimal disease but has a substantial acute postoperative mortality rate and greater morbidity than irradiation. Combining surgery and either preoperative or postoperative irradiation may cure a small percentage of patients beyond the number cured with either modality alone. Radiation has demonstrated benefit as an adjuvant to surgery following the resection of minimal disease. However, radiation alone has never been compared directly with surgery for the highly select, minimal lesions managed by surgery. Radiation provides good palliation of dysphagia in the majority of patients, and roughly one third may have adequate swallowing for the duration of their illness when "radical" doses have been employed. Surgical bypass procedures have greater acute morbidity but appear to provide more reliable, prolonged palliation of dysphagia. They constitute the best approach for patients with persistent or recurrent dysphagia following esophageal irradiation. Several approaches to improving the efficacy of irradiation are currently under investigation. Fewer large fractions appear to be equivalent to conventionally fractionated radiotherapy in terms of local control and survival but produce more prompt palliation and shorten courses of palliative therapy. Multiple-daily-fractionation schedules and hyperfractionation have theoretical appeal and clear basis for investigation from the early suggestions of improved response rates in advanced squamous-cell cancer of the head and neck. Hypoxic-cell radiosensitizers, neutron-beam, and helium-ion therapy results have not been overly encouraging in esophageal cancer, thus far. However, the new generation of particle beams and the new radiation-sensitizer drugs require further evaluation. Better means of dealing with the high incidence of disseminated disease are clearly needed. It is clear that combined-modality approaches using both local and systemic therapy will ultimately be desirable in esophageal-cancer treatment.(ABSTRACT TRUNCATED AT 400 WORDS)
D001918:Brachytherapy; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000532:radiotherapy*; D004947:Esophagus / Q000000981:diagnostic imaging / Q000601:surgery; D006801:Humans; D009362:Neoplasm Metastasis; D010166:Palliative Care; D010347:Patient Care Planning; D011182:Postoperative Care; D011300:Preoperative Care; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy / Q000401:mortality; D014057:Tomography, X-Ray Computed
D011838:Radiation-Sensitizing Agents